Peptomyc opens a 25 million round of investment and secures 8.6 million euros from its current partners

The spin-off from VHIO (Vall d'Hebron Institute of Oncology) and ICREA – Peptomyc – which has developed the first oncological treatment based on MYC inhibition, is about to finish a phase I clinical trial and is gearing up for phase II with a financing round of 25 million euros. Its current partners – Healthequity, Alta Life Sciences, Aurora Science, the CDTI and several Business Angels – have already committed 8.6 million in this round through a convertible loan, confirming their enthusiasm and support for this project.

The company has come a long way since its last round of investment of 11.4 million € in 2020: the phase I trial of its first drug, OMO-103, is nearing completion in three hospitals in Madrid and Barcelona, aiming to demonstrate safety and detect the first signs of efficacy in patients with all types of solid tumours that have exhausted previous lines of treatment and lack further therapeutic options.

Once this study is finished, OMO-103 will advance to phase II, where its efficacy will be verified in more patients and at least three oncological indications. The founders, Laura Soucek and Marie-Eve Beaulieu, comment that this is a very exciting moment for the entire team, who are finally confirming in patients the highly promising results observed in preclinical models, and highlight how this first MYC inhibitor is attracting interest from investors and Big Pharma, which would like to have this first-in-class in their portfolio.